Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Novo Nordisk A/S. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$745.86 -9.71 (-1.29%)
As of 05/13/2025 03:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company has shown significant revenue growth, with a year-over-year increase of over 45%, indicating strong demand for its products.
  • Eli Lilly and Co recently reported a quarterly earnings per share (EPS) of $3.34, which, despite missing estimates, reflects a solid performance compared to the previous year's EPS of $2.58.
  • The current stock price is around $736, which may present a buying opportunity for investors looking to enter at a lower price point after recent fluctuations.

Cons of Eli Lilly and Company

  • The stock price has experienced a decline of about 2% recently, which may indicate short-term volatility and uncertainty in the market.
  • The company missed analysts' consensus estimates for both EPS and revenue in its latest quarterly report, which could raise concerns about its growth trajectory.
  • With a high price-to-earnings (P/E) ratio of 62.87, the stock may be considered overvalued, suggesting that investors could be paying a premium for future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$706.88 billion
P/E Ratio
63.69
Consensus Rating
Moderate Buy
Consensus Price Target
$1,011.37 (+35.6% Upside)
Volume
4.48 million shares
Average Volume
3.54 million shares
Today's Range
$740.85
$759.50
50-Day Range
$719.85
$899.78
52-Week Range
$677.09
$972.53
Dividend Yield
0.80%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$148.71 -5.43 (-3.52%)
As of 05/13/2025 03:53 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $155, which may present a buying opportunity for investors looking for value in a well-established company.
  • Johnson & Johnson recently reported strong earnings, exceeding analysts' expectations with earnings per share of $2.77, indicating robust financial health and operational efficiency.
  • The company has a solid market capitalization of approximately $374 billion, reflecting its stability and significant presence in the healthcare sector.

Cons of Johnson & Johnson

  • The stock has experienced fluctuations, with a 1-year low of $140.68, which may raise concerns about its volatility and market performance.
  • Johnson & Johnson's price-to-earnings ratio is around 23.40, which could be considered high compared to industry averages, suggesting that the stock may be overvalued.
  • Recent insider selling, including shares sold by Representative Gilbert Ray Cisneros, Jr., may indicate a lack of confidence among insiders regarding the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$357.81 billion
P/E Ratio
22.36
Consensus Rating
Moderate Buy
Consensus Price Target
$170.88 (+14.9% Upside)
Volume
10.44 million shares
Average Volume
7.89 million shares
Today's Range
$148.08
$151.70
50-Day Range
$148.62
$167.57
52-Week Range
$140.68
$169.99
Dividend Yield
3.19%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$187.95 -2.12 (-1.12%)
As of 05/13/2025 03:59 PM Eastern

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received a strong consensus rating from analysts, with a majority recommending a buy or strong buy, indicating positive market sentiment.
  • The current stock price is around $184, which may present a buying opportunity for investors looking for value in a well-rated stock.
  • The company reported earnings per share of $2.46, exceeding analyst expectations, which reflects strong financial performance and potential for growth.

Cons of AbbVie

  • The stock has experienced a recent decline of about 0.7%, which may indicate short-term volatility and investor uncertainty.
  • Insider selling has been notable, with executives selling a significant number of shares, which could signal a lack of confidence in the company's short-term prospects.
  • AbbVie has a high P/E ratio of 76.79, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$332.48 billion
P/E Ratio
78.31
Consensus Rating
Moderate Buy
Consensus Price Target
$211.41 (+12.5% Upside)
Volume
7.52 million shares
Average Volume
6.15 million shares
Today's Range
$185.41
$189.76
50-Day Range
$170.01
$216.62
52-Week Range
$153.58
$218.66
Dividend Yield
3.53%
Novo Nordisk A/S stock logo

4. Novo Nordisk A/S NYSE:NVO

$65.38 -2.36 (-3.48%)
As of 05/13/2025 03:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $67, reflecting a recent increase of 3.5%, which may indicate positive market sentiment.
  • Analysts have a consensus rating of "Moderate Buy" for Novo Nordisk, suggesting that many believe the stock has potential for growth.
  • The company reported a strong return on equity of 84.68%, indicating effective management and profitability, which can be attractive to investors.

Cons of Novo Nordisk A/S

  • The stock has experienced a decline in trading volume, which may indicate reduced investor interest or confidence.
  • Recent earnings reports showed revenue that fell short of expectations, which could raise concerns about the company's growth trajectory.
  • Analysts have issued a mix of ratings, including sell and hold ratings, which may reflect uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$293.39 billion
P/E Ratio
19.87
Consensus Rating
Hold
Consensus Price Target
$135.00 (+106.5% Upside)
Volume
10.34 million shares
Average Volume
6.42 million shares
Today's Range
$64.95
$66.63
50-Day Range
$57.99
$87.19
52-Week Range
$57.00
$148.15
Dividend Yield
2.43%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$311.23 -67.52 (-17.83%)
As of 05/13/2025 03:59 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company has received multiple positive ratings from analysts, with a consensus rating of "Moderate Buy" and a target price around $596.86, indicating potential for price appreciation.
  • UnitedHealth Group recently reported a strong return on equity of 26.69%, suggesting effective management and profitability, which can be attractive to investors looking for solid financial performance.
  • The current stock price is approximately $384.25, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $630.73.

Cons of UnitedHealth Group

  • Recent earnings reports showed that the company missed consensus estimates, which could raise concerns about its ability to meet future financial expectations.
  • Analysts have recently downgraded their price targets, with some estimates dropping significantly, indicating a potential lack of confidence in the stock's near-term performance.
  • The stock has experienced volatility, with a significant drop from its 52-week high, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$282.33 billion
P/E Ratio
20.08
Consensus Rating
Moderate Buy
Consensus Price Target
$596.86 (+91.8% Upside)
Volume
59.03 million shares
Average Volume
4.95 million shares
Today's Range
$309.10
$342.00
50-Day Range
$311.23
$599.10
52-Week Range
$309.10
$630.73
Dividend Yield
2.18%
Novartis stock logo

6. Novartis NYSE:NVS

$106.85 -2.10 (-1.93%)
As of 05/13/2025 03:59 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $110, which is near its fifty-two week high of $120.92, indicating strong market performance.
  • Novartis AG recently reported earnings that exceeded analysts' expectations, showcasing robust financial health and a return on equity of over 37%, which reflects effective management and profitability.
  • The company has a solid market capitalization of approximately $232 billion, suggesting stability and a strong position in the pharmaceutical industry.

Cons of Novartis

  • Several analysts have issued "underweight" ratings, indicating concerns about the stock's performance relative to the market.
  • Despite recent earnings growth, the company faces competitive pressures in the pharmaceutical sector, which could impact future revenue streams.
  • The stock has shown volatility, with a beta of 0.60, suggesting it may not be as stable as some investors prefer.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$225.71 billion
P/E Ratio
18.17
Consensus Rating
Hold
Consensus Price Target
$123.38 (+15.5% Upside)
Volume
1.75 million shares
Average Volume
1.57 million shares
Today's Range
$106.65
$108.44
50-Day Range
$101.80
$115.60
52-Week Range
$96.06
$120.92
Dividend Yield
2.36%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$129.02 -2.97 (-2.25%)
As of 05/13/2025 03:59 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $133.50, reflecting a strong market position and potential for growth.
  • Abbott Laboratories has recently reported earnings that exceeded analyst expectations, indicating robust financial health and operational efficiency.
  • The company has a solid dividend yield of approximately 1.76%, providing a steady income stream for investors.

Cons of Abbott Laboratories

  • Despite strong earnings, the revenue reported was slightly below analyst estimates, which may raise concerns about future growth.
  • Insider selling activity has been noted, with significant shares sold recently, which could indicate a lack of confidence among executives.
  • The company's debt-to-equity ratio is relatively low at 0.32, which is generally positive, but it may limit aggressive growth strategies.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$224.47 billion
P/E Ratio
16.87
Consensus Rating
Moderate Buy
Consensus Price Target
$142.59 (+10.5% Upside)
Volume
6.34 million shares
Average Volume
6.10 million shares
Today's Range
$128.92
$131.75
50-Day Range
$123.63
$137.43
52-Week Range
$99.71
$141.23
Dividend Yield
1.76%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$67.72 -1.23 (-1.78%)
As of 05/13/2025 04:00 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $70, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • AstraZeneca has recently reported strong earnings, with earnings per share (EPS) exceeding analyst expectations, indicating robust financial health and potential for future growth.
  • The company has a solid market capitalization of approximately $217.30 billion, reflecting its stability and established presence in the industry.

Cons of AstraZeneca

  • The stock has experienced fluctuations, with a 52-week high of $87.68 and a low of $61.24, indicating potential volatility that could affect investment returns.
  • The company has a quick ratio of 0.74 and a current ratio of 0.93, suggesting potential liquidity concerns that may impact its ability to meet short-term obligations.
  • AstraZeneca's price-to-earnings (P/E) ratio is 31.00, which may be considered high compared to industry averages, potentially indicating that the stock is overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$210.02 billion
P/E Ratio
29.96
Consensus Rating
Buy
Consensus Price Target
$88.00 (+29.9% Upside)
Volume
4.83 million shares
Average Volume
5.14 million shares
Today's Range
$67.39
$68.44
50-Day Range
$64.87
$77.60
52-Week Range
$61.24
$87.68
Dividend Yield
2.93%
Intuitive Surgical stock logo

9. Intuitive Surgical NASDAQ:ISRG

$563.95 +2.52 (+0.45%)
As of 05/13/2025 04:00 PM Eastern

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $536.55, which reflects a strong market position and potential for growth.
  • Intuitive Surgical, Inc. reported earnings per share (EPS) of $1.81, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a high net margin of 27.81%, suggesting efficient management and profitability, which can lead to higher returns for investors.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings (P/E) ratio of 83.71, which may indicate that the stock is overvalued compared to its earnings.
  • Recent insider sales totaling over 33,000 shares could suggest a lack of confidence from those within the company.
  • The stock price has shown volatility, with a 1-year high of $616.00 and a low of $379.67, indicating potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$202.13 billion
P/E Ratio
87.98
Consensus Rating
Moderate Buy
Consensus Price Target
$598.95 (+6.2% Upside)
Volume
1.53 million shares
Average Volume
1.63 million shares
Today's Range
$559.88
$568.69
50-Day Range
$451.58
$563.95
52-Week Range
$379.67
$616.00
Dividend Yield
N/A
Merck & Co., Inc. stock logo

10. Merck & Co., Inc. NYSE:MRK

$76.62 -3.81 (-4.74%)
As of 05/13/2025 03:59 PM Eastern

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $75.88, which may present a buying opportunity for investors looking for value.
  • Merck has a strong market capitalization of approximately $190 billion, indicating a solid position in the pharmaceutical industry.
  • Recent institutional investments, including a significant stake increase by Crestline Management LP, suggest growing confidence in Merck's future performance.

Cons of Merck & Co., Inc.

  • The stock has experienced a decline of about 2.3% recently, which may raise concerns about short-term performance.
  • Merck's debt-to-equity ratio of 0.79 suggests a moderate level of debt, which could impact financial stability in uncertain market conditions.
  • Recent analyst reports have lowered target prices, indicating some analysts may have a less optimistic view of the company's growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$192.40 billion
P/E Ratio
11.38
Consensus Rating
Moderate Buy
Consensus Price Target
$111.13 (+45.0% Upside)
Volume
23.35 million shares
Average Volume
12.24 million shares
Today's Range
$76.56
$78.55
50-Day Range
$75.88
$95.13
52-Week Range
$75.82
$134.63
Dividend Yield
4.17%
Thermo Fisher Scientific stock logo

11. Thermo Fisher Scientific NYSE:TMO

$428.88 -3.71 (-0.86%)
As of 05/13/2025 04:00 PM Eastern

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $532, reflecting a strong market position and investor confidence in the company's growth potential.
  • Recent insider trading activity indicates confidence among executives, with significant share ownership remaining after recent sales, suggesting they believe in the company's future performance.
  • Thermo Fisher Scientific Inc. continues to expand its product offerings in life sciences solutions and analytical instruments, which are critical in the growing biopharma sector.

Cons of Thermo Fisher Scientific

  • Insider sales, while not uncommon, can raise concerns about the executives' confidence in the company's short-term performance, as seen with recent transactions.
  • The stock has experienced fluctuations, which may indicate volatility and uncertainty in the market, potentially affecting investor returns.
  • With only 0.33% of the stock owned by corporate insiders, there may be a lack of alignment between management and shareholder interests, which can be a red flag for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$161.90 billion
P/E Ratio
25.95
Consensus Rating
Moderate Buy
Consensus Price Target
$607.43 (+41.6% Upside)
Volume
2.73 million shares
Average Volume
1.81 million shares
Today's Range
$427.30
$434.98
50-Day Range
$402.93
$531.74
52-Week Range
$401.75
$627.88
Dividend Yield
0.42%
Boston Scientific stock logo

12. Boston Scientific NYSE:BSX

$102.92 +0.05 (+0.05%)
As of 05/13/2025 03:59 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $106.31, which reflects a strong market position and potential for growth.
  • Recent analyst upgrades have increased price targets, with some analysts setting targets as high as $130.00, indicating confidence in the company's future performance.
  • Boston Scientific Co. has a diverse product portfolio in the medical device sector, particularly in interventional medical specialties, which can lead to stable revenue streams.

Cons of Boston Scientific

  • Insider sales have been notable, with executives selling a significant number of shares, which could signal a lack of confidence in the stock's short-term performance.
  • Despite positive analyst ratings, the stock has experienced fluctuations, which may indicate volatility and risk for investors.
  • Only 0.50% of the stock is owned by company insiders, suggesting limited alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.26 billion
P/E Ratio
82.34
Consensus Rating
Buy
Consensus Price Target
$114.52 (+11.3% Upside)
Volume
7.06 million shares
Average Volume
6.32 million shares
Today's Range
$102.26
$103.68
50-Day Range
$89.78
$104.94
52-Week Range
$71.88
$107.17
Dividend Yield
N/A
Stryker stock logo

13. Stryker NYSE:SYK

$387.92 -0.16 (-0.04%)
As of 05/13/2025 03:59 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Recent analyst upgrades have set target prices for Stryker Co. as high as $450, indicating strong potential for price appreciation.
  • The current stock price is around $380, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Stryker Co. has a significant institutional ownership of 77.09%, suggesting confidence from large investors in the company's future performance.

Cons of Stryker

  • Insider selling activity, including significant sales by directors, may raise concerns about the company's short-term outlook and could indicate a lack of confidence among insiders.
  • Recent fluctuations in stock price, with a slight decline of about 0.4% during recent trading, may suggest volatility that could deter risk-averse investors.
  • Some analysts have issued hold ratings, indicating that while the stock has potential, it may not be the best investment at this time compared to other opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$148.06 billion
P/E Ratio
49.99
Consensus Rating
Moderate Buy
Consensus Price Target
$427.05 (+10.1% Upside)
Volume
862,573 shares
Average Volume
1.35 million shares
Today's Range
$385.78
$390.46
50-Day Range
$336.96
$387.97
52-Week Range
$314.93
$406.19
Dividend Yield
0.88%
Amgen stock logo

14. Amgen NASDAQ:AMGN

$270.45 -4.31 (-1.57%)
As of 05/13/2025 04:00 PM Eastern

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $265.86, which may present a buying opportunity for investors looking for value in the biotech sector.
  • Amgen Inc. has a strong market capitalization of approximately $142.94 billion, indicating a solid position in the industry and potential for growth.
  • Recent ratings from analysts show a consensus rating of "Hold," suggesting that while there may not be immediate bullish sentiment, the stock is considered stable.

Cons of Amgen

  • Analysts have recently downgraded Amgen Inc. from "strong-buy" to "hold," indicating a lack of confidence in short-term price increases.
  • Two analysts have issued sell ratings, which may signal potential risks or concerns about the company's future performance.
  • The stock has experienced fluctuations, with a 52-week low of $253.30, suggesting volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.42 billion
P/E Ratio
35.82
Consensus Rating
Hold
Consensus Price Target
$310.23 (+14.7% Upside)
Volume
2.66 million shares
Average Volume
2.77 million shares
Today's Range
$268.53
$273.92
50-Day Range
$265.86
$327.36
52-Week Range
$253.30
$346.85
Dividend Yield
3.50%
Danaher stock logo

15. Danaher NYSE:DHR

$196.60 -4.23 (-2.11%)
As of 05/13/2025 03:59 PM Eastern

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The company recently reported earnings per share (EPS) of $1.88, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Danaher Co. has a solid revenue stream, with reported revenues of $5.74 billion, surpassing market expectations, showcasing its ability to generate income effectively.
  • The current stock price is around $198, which may present a buying opportunity for investors looking for growth in a well-performing company.

Cons of Danaher

  • Insider ownership is relatively low at 11.10%, which may raise concerns about alignment between management and shareholder interests.
  • Recent insider transactions indicate a significant decrease in ownership by executives, which could signal a lack of confidence in the company's future performance.
  • Analysts have recently adjusted their price targets downward, with some reducing their expectations for the stock, which may indicate potential volatility ahead.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.70 billion
P/E Ratio
37.23
Consensus Rating
Moderate Buy
Consensus Price Target
$264.40 (+34.5% Upside)
Volume
2.65 million shares
Average Volume
3.42 million shares
Today's Range
$196.36
$201.72
50-Day Range
$173.85
$212.97
52-Week Range
$171.00
$281.70
Dividend Yield
0.66%
Pfizer stock logo

16. Pfizer NYSE:PFE

$22.86 -0.23 (-1.00%)
As of 05/13/2025 03:59 PM Eastern

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $22.28, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. has a strong dividend yield of approximately 7.72%, providing a steady income stream for investors, which is particularly attractive in a low-interest-rate environment.
  • Recent institutional investments indicate growing confidence in Pfizer Inc., with several firms purchasing significant stakes, suggesting potential for future growth.

Cons of Pfizer

  • The company's dividend payout ratio is currently at 124.64%, which means it is paying out more in dividends than it earns, raising concerns about sustainability.
  • Recent trading activity shows a decline of about 3.0%, which may indicate market volatility and investor uncertainty regarding the stock's future performance.
  • Insider ownership is relatively low at 0.06%, which may suggest a lack of confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$129.97 billion
P/E Ratio
16.21
Consensus Rating
Moderate Buy
Consensus Price Target
$29.17 (+27.6% Upside)
Volume
39.24 million shares
Average Volume
40.52 million shares
Today's Range
$22.49
$22.98
50-Day Range
$21.57
$26.71
52-Week Range
$20.92
$31.54
Dividend Yield
7.49%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$101.43 -2.39 (-2.30%)
As of 05/13/2025 04:00 PM Eastern

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $110, which is significantly lower than its 1-year high of $119.96, potentially offering a buying opportunity for investors looking for value.
  • Gilead Sciences, Inc. recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and effective management strategies.
  • The company has a solid dividend yield of approximately 3.20%, providing investors with a steady income stream, which is particularly attractive in a low-interest-rate environment.

Cons of Gilead Sciences

  • The company's quarterly revenue showed a slight decline of 0.3% year-over-year, which may raise concerns about its growth trajectory and market competitiveness.
  • Despite beating earnings expectations, the revenue reported was below analyst estimates, indicating potential challenges in meeting future growth targets.
  • Gilead Sciences, Inc. has a relatively high dividend payout ratio of 66.53%, which could limit its ability to reinvest in growth opportunities or weather economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$126.30 billion
P/E Ratio
274.14
Consensus Rating
Moderate Buy
Consensus Price Target
$110.55 (+9.0% Upside)
Volume
8.31 million shares
Average Volume
7.59 million shares
Today's Range
$100.73
$102.83
50-Day Range
$96.86
$117.41
52-Week Range
$62.07
$119.96
Dividend Yield
3.22%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$49.96 -1.10 (-2.15%)
As of 05/13/2025 04:00 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi recently reported a quarterly earnings per share (EPS) of $0.94, surpassing expectations, which indicates strong financial performance and potential for growth.
  • The current stock price is around $54, which is near its 52-week high of $60.12, suggesting positive market sentiment and potential for further appreciation.
  • Sanofi has increased its annual dividend to $2.0369 per share, reflecting a commitment to returning value to shareholders and a healthy dividend yield of approximately 3.1%.

Cons of Sanofi

  • Sanofi's revenue has decreased by 11% compared to the same quarter last year, which may raise concerns about its ability to maintain growth in a competitive market.
  • The company has a relatively low debt-to-equity ratio of 0.15, which indicates conservative financial leverage but may also suggest limited aggressive growth strategies.
  • Despite recent upgrades, some analysts still maintain a "hold" rating, indicating uncertainty about the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$126.21 billion
P/E Ratio
20.06
Consensus Rating
Buy
Consensus Price Target
$63.33 (+26.8% Upside)
Volume
2.97 million shares
Average Volume
2.37 million shares
Today's Range
$49.84
$50.71
50-Day Range
$49.66
$59.35
52-Week Range
$45.80
$60.12
Dividend Yield
2.84%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$432.00 -7.37 (-1.68%)
As of 05/13/2025 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $425, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals has a strong market capitalization of over $109 billion, indicating a solid position in the industry and potential for stability.
  • Recent upgrades from analysts, including a shift from "hold" to "buy" ratings, suggest positive sentiment and potential for stock appreciation.

Cons of Vertex Pharmaceuticals

  • The stock has experienced volatility, with a recent trading down of about 1%, which may concern risk-averse investors.
  • Analysts have issued mixed ratings, with some downgrading the stock from "strong-buy" to "hold," indicating uncertainty about future performance.
  • The company reported earnings that missed consensus estimates, which could signal potential challenges in meeting growth expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$110.94 billion
P/E Ratio
-196.36
Consensus Rating
Moderate Buy
Consensus Price Target
$515.04 (+19.2% Upside)
Volume
2.65 million shares
Average Volume
1.40 million shares
Today's Range
$429.54
$442.12
50-Day Range
$425.30
$513.76
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

20. Medtronic NYSE:MDT

$85.26 -0.55 (-0.64%)
As of 05/13/2025 03:53 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $83.50, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Medtronic plc recently reported earnings that exceeded analysts' expectations, indicating strong operational performance and potential for future growth.
  • The company has a solid market capitalization of over $107 billion, reflecting its stability and established presence in the healthcare industry.

Cons of Medtronic

  • Despite recent earnings growth, the company's revenue fell short of analyst expectations, which could indicate challenges in meeting future sales targets.
  • Medtronic plc has a relatively high dividend payout ratio of 85.11%, which may raise concerns about sustainability, especially in times of economic uncertainty.
  • The stock has experienced volatility, with a 52-week high of $96.25 and a low of $75.96, suggesting potential risks for investors seeking stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$109.35 billion
P/E Ratio
25.91
Consensus Rating
Hold
Consensus Price Target
$96.14 (+12.8% Upside)
Volume
5.53 million shares
Average Volume
6.71 million shares
Today's Range
$84.81
$85.80
50-Day Range
$81.64
$94.58
52-Week Range
$75.96
$96.25
Dividend Yield
3.35%
Bristol-Myers Squibb stock logo

21. Bristol-Myers Squibb NYSE:BMY

$46.58 -1.60 (-3.32%)
As of 05/13/2025 03:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • The current stock price is around $58, which is considered attractive by analysts, with a consensus target price suggesting potential upside.
  • Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which could drive future revenue growth.
  • The company offers a solid annualized dividend of $2.48, providing a dividend yield of approximately 5.30%, which can be appealing for income-focused investors.

Cons of Bristol-Myers Squibb

  • The dividend payout ratio is currently high at approximately 92.88%, which may raise concerns about the sustainability of future dividend payments.
  • Recent research reports show a mix of ratings, with a significant number of analysts maintaining a "hold" rating, indicating uncertainty about the stock's short-term performance.
  • Some analysts have downgraded their price targets, reflecting concerns about potential challenges in the competitive biopharmaceutical landscape.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.79 billion
P/E Ratio
-10.54
Consensus Rating
Hold
Consensus Price Target
$58.00 (+24.5% Upside)
Volume
16.68 million shares
Average Volume
13.12 million shares
Today's Range
$46.51
$47.63
50-Day Range
$46.38
$63.00
52-Week Range
$39.35
$63.33
Dividend Yield
5.29%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$368.33 +5.05 (+1.39%)
As of 05/13/2025 03:59 PM Eastern

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The company recently reported earnings per share (EPS) of $6.45, significantly exceeding analyst expectations, indicating strong financial performance.
  • HCA Healthcare, Inc. has shown a robust revenue growth of 5.7% compared to the same quarter last year, reflecting its ability to expand and attract more patients.
  • The current stock price is around $381, which is considered attractive given the company's strong fundamentals and growth prospects.

Cons of HCA Healthcare

  • Despite strong earnings, some analysts have downgraded their target prices for the stock, indicating potential concerns about future performance.
  • The company has a relatively low dividend yield of 0.81%, which may not be appealing for income-focused investors.
  • There is a mix of ratings from analysts, with some maintaining a "hold" rating, suggesting uncertainty about the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.61 billion
P/E Ratio
16.77
Consensus Rating
Moderate Buy
Consensus Price Target
$381.13 (+3.5% Upside)
Volume
2.20 million shares
Average Volume
1.40 million shares
Today's Range
$361.45
$372.94
50-Day Range
$313.49
$368.33
52-Week Range
$289.98
$417.14
Dividend Yield
0.81%
McKesson stock logo

23. McKesson NYSE:MCK

$687.93 +0.41 (+0.06%)
As of 05/13/2025 03:59 PM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $694, reflecting a stable market position and potential for growth.
  • Recent earnings results showed a significant increase in revenue, with a year-over-year growth of nearly 19%, indicating strong operational performance.
  • Analysts have a consensus rating of "Moderate Buy" with a price target averaging around $686.69, suggesting potential upside for investors.

Cons of McKesson

  • The company has a negative return on equity of over 181%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Insider selling has been notable, with executives recently selling significant shares, which could indicate a lack of confidence in the company's short-term prospects.
  • Despite revenue growth, the company reported earnings that fell short of analyst expectations, which may signal challenges in meeting future performance targets.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$86.16 billion
P/E Ratio
31.50
Consensus Rating
Moderate Buy
Consensus Price Target
$686.69 (-0.2% Downside)
Volume
1.14 million shares
Average Volume
906,216 shares
Today's Range
$682.86
$696.98
50-Day Range
$640.93
$721.98
52-Week Range
$464.42
$728.48
Dividend Yield
0.41%
Elevance Health stock logo

24. Elevance Health NYSE:ELV

$375.07 -41.62 (-9.99%)
As of 05/13/2025 03:59 PM Eastern

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$84.74 billion
P/E Ratio
14.65
Consensus Rating
Moderate Buy
Consensus Price Target
$510.38 (+36.1% Upside)
Volume
3.57 million shares
Average Volume
1.48 million shares
Today's Range
$374.78
$399.78
50-Day Range
$375.07
$452.70
52-Week Range
$362.21
$567.26
Dividend Yield
1.66%
The Cigna Group stock logo

25. The Cigna Group NYSE:CI

$301.90 -13.84 (-4.38%)
As of 05/13/2025 03:59 PM Eastern

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The Cigna Group has recently reported strong quarterly earnings, with earnings per share exceeding analysts' expectations, indicating robust financial performance.
  • The stock has a favorable market cap of approximately $89.17 billion, suggesting a stable and significant presence in the market.
  • Recent analyst ratings have been positive, with multiple firms issuing "buy" and "strong-buy" ratings, reflecting confidence in the company's growth potential.

Cons of The Cigna Group

  • The stock has experienced fluctuations, with a 12-month high of $370.83, suggesting potential volatility that could affect investment returns.
  • Despite positive earnings, the company's net margin is relatively low at 1.39%, which may raise concerns about profitability compared to competitors.
  • Analysts have varying target prices, with some estimates as low as $375, indicating uncertainty in future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.65 billion
P/E Ratio
24.67
Consensus Rating
Buy
Consensus Price Target
$379.33 (+25.6% Upside)
Volume
3.07 million shares
Average Volume
1.70 million shares
Today's Range
$301.48
$310.25
50-Day Range
$301.90
$340.21
52-Week Range
$262.03
$370.83
Dividend Yield
1.81%
CVS Health stock logo

26. CVS Health NYSE:CVS

$60.50 -4.31 (-6.65%)
As of 05/13/2025 03:59 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has received multiple upgrades from analysts, with recent price targets reaching as high as $81.00, indicating strong market confidence in the company's growth potential.
  • The current stock price is around $66.98, which is significantly higher than its one-year low of $43.56, suggesting a positive trend in the stock's performance.
  • Seventeen analysts have issued buy ratings for CVS Health Co., reflecting a strong consensus among market experts about the company's future prospects.

Cons of CVS Health

  • Despite the positive outlook, the stock has experienced fluctuations, with a recent decline of about 1.3%, indicating potential volatility in the short term.
  • Insider trading activity shows mixed signals, as a senior vice president sold a significant number of shares, which could raise concerns about the company's future performance from an insider perspective.
  • The company's quick ratio of 0.60 suggests that it may face challenges in meeting short-term liabilities, which could impact liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.53 billion
P/E Ratio
16.53
Consensus Rating
Moderate Buy
Consensus Price Target
$75.27 (+24.4% Upside)
Volume
19.15 million shares
Average Volume
11.43 million shares
Today's Range
$60.30
$62.81
50-Day Range
$60.50
$70.40
52-Week Range
$43.56
$72.51
Dividend Yield
3.92%
GSK stock logo

27. GSK NYSE:GSK

$36.36 -1.01 (-2.70%)
As of 05/13/2025 03:59 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $38.79, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $1.13, indicating robust financial performance.
  • The company has increased its quarterly dividend to $0.4216 per share, reflecting a commitment to returning value to shareholders and a healthy dividend yield of approximately 4.58%.

Cons of GSK

  • One analyst has rated GSK plc with a "sell" rating, which may indicate concerns about the company's future performance.
  • The stock has experienced fluctuations, with a 52-week high of $45.93 and a low of $31.72, suggesting volatility that could deter risk-averse investors.
  • GSK plc has a debt-to-equity ratio of 1.12, which indicates a relatively high level of debt compared to equity, potentially raising concerns about financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$75.02 billion
P/E Ratio
22.87
Consensus Rating
Hold
Consensus Price Target
$40.58 (+11.6% Upside)
Volume
5.08 million shares
Average Volume
4.78 million shares
Today's Range
$36.17
$36.69
50-Day Range
$33.65
$40.41
52-Week Range
$31.72
$45.93
Dividend Yield
4.34%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$160.43 -1.49 (-0.92%)
As of 05/13/2025 03:59 PM Eastern

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $161.77, which reflects a strong market position and potential for growth.
  • Analysts have a consensus rating of "Buy" for Zoetis Inc., indicating positive sentiment and confidence in the company's future performance.
  • Recent upgrades from multiple analysts, including Piper Sandler raising their price target to $205.00, suggest that the stock is viewed favorably in the market.

Cons of Zoetis

  • Insider selling activity has been noted, with a total of 1,862 shares sold recently, which may raise concerns about the confidence of current executives in the company's future.
  • Some analysts have set lower price targets, such as UBS Group reducing their target to $170.00, indicating potential volatility in stock performance.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 29.57, which may suggest that it is overvalued compared to its earnings, making it a riskier investment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.09 billion
P/E Ratio
29.33
Consensus Rating
Buy
Consensus Price Target
$212.75 (+32.6% Upside)
Volume
3.34 million shares
Average Volume
2.49 million shares
Today's Range
$160.06
$162.91
50-Day Range
$144.09
$171.70
52-Week Range
$139.70
$200.33
Dividend Yield
1.26%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$574.16 -1.47 (-0.26%)
As of 05/13/2025 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $624, which is significantly lower than its 52-week high of $1,211.20, potentially offering a buying opportunity for investors looking for value.
  • Regeneron Pharmaceuticals, Inc. has a strong market capitalization of approximately $61.94 billion, indicating a solid position in the biopharmaceutical industry.
  • The company reported a net margin of over 31%, showcasing its ability to convert revenue into profit effectively, which is attractive for investors seeking profitability.

Cons of Regeneron Pharmaceuticals

  • The company recently reported earnings per share (EPS) of $8.22, which fell short of the consensus estimate of $8.83, indicating potential challenges in meeting market expectations.
  • Regeneron Pharmaceuticals, Inc. experienced a revenue decline of 3.7% compared to the same quarter last year, raising concerns about its growth trajectory in a competitive market.
  • Analysts have downgraded the stock's price target, with some firms reducing their expectations significantly, which may signal a lack of confidence in the company's near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$62.77 billion
P/E Ratio
15.00
Consensus Rating
Moderate Buy
Consensus Price Target
$892.60 (+55.5% Upside)
Volume
1.08 million shares
Average Volume
774,854 shares
Today's Range
$558.45
$575.05
50-Day Range
$527.78
$744.83
52-Week Range
$520.50
$1,211.20
Dividend Yield
0.16%
Cencora stock logo

30. Cencora NYSE:COR

$279.00 +0.62 (+0.22%)
As of 05/13/2025 03:59 PM Eastern

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $276, which reflects a strong market position and potential for growth.
  • Recent analyst upgrades have increased target prices significantly, indicating positive market sentiment and confidence in the company's future performance.
  • Institutional investors and hedge funds own a substantial 97.52% of the company's stock, suggesting strong backing and confidence from major financial players.

Cons of Cencora

  • The company has a high P/E ratio of 40.27, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider trading activity has shown recent sales, with executives reducing their ownership stakes, which could indicate a lack of confidence in the company's short-term prospects.
  • The quick ratio of 0.54 suggests that the company may have liquidity issues, meaning it might struggle to meet short-term obligations without selling inventory or obtaining additional financing.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.10 billion
P/E Ratio
39.69
Consensus Rating
Moderate Buy
Consensus Price Target
$301.18 (+8.0% Upside)
Volume
1.98 million shares
Average Volume
1.53 million shares
Today's Range
$276.17
$280.19
50-Day Range
$253.51
$304.04
52-Week Range
$214.77
$309.35
Dividend Yield
0.78%
Becton, Dickinson and Company stock logo

31. Becton, Dickinson and Company NYSE:BDX

$175.32 -0.02 (-0.01%)
As of 05/13/2025 03:59 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $167, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Becton, Dickinson and Company has a strong market capitalization of approximately $48 billion, indicating a solid position in the industry.
  • The company has a consistent dividend payout, with an annualized dividend of $4.16, providing a yield of 2.49%, which can be attractive for income-focused investors.

Cons of Becton, Dickinson and Company

  • Several analysts have downgraded the stock recently, with ratings shifting from "buy" to "neutral," which may indicate a lack of confidence in short-term performance.
  • The company's payout ratio is currently at 79.39%, suggesting that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Recent trading activity shows the stock has experienced fluctuations, with a 52-week low of $163.33, indicating potential volatility that could concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.25 billion
P/E Ratio
29.12
Consensus Rating
Hold
Consensus Price Target
$231.44 (+32.0% Upside)
Volume
3.77 million shares
Average Volume
1.87 million shares
Today's Range
$172.30
$177.80
50-Day Range
$165.13
$232.12
52-Week Range
$163.33
$251.99
Dividend Yield
2.48%
Haleon stock logo

32. Haleon NYSE:HLN

$10.46 -0.25 (-2.33%)
As of 05/13/2025 03:59 PM Eastern

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $10.75, which is near its one-year high, indicating strong market performance.
  • Haleon plc has recently reported earnings that exceeded analysts' expectations, showcasing its ability to generate revenue effectively.
  • Several analysts have upgraded their ratings on Haleon plc, with a consensus rating of "Moderate Buy," suggesting positive market sentiment.

Cons of Haleon

  • Despite recent upgrades, some analysts have maintained a "hold" rating, suggesting caution in the stock's potential for immediate growth.
  • The stock has experienced fluctuations, with a one-year low of $8.24, indicating volatility that could concern risk-averse investors.
  • Haleon plc's price-to-earnings ratio is relatively high, which may suggest that the stock is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.18 billion
P/E Ratio
30.76
Consensus Rating
Moderate Buy
Consensus Price Target
$11.25 (+7.6% Upside)
Volume
18.05 million shares
Average Volume
7.83 million shares
Today's Range
$10.42
$10.57
50-Day Range
$9.28
$10.77
52-Week Range
$8.25
$10.85
Dividend Yield
2.21%
Alcon stock logo

33. Alcon NYSE:ALC

$93.48 -1.31 (-1.38%)
As of 05/13/2025 03:59 PM Eastern

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is approximately $91.50, reflecting a strong market position and potential for growth.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a solid upward trend in its stock value.
  • Institutional ownership is significant, suggesting that large investors have confidence in the company's future prospects.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which may indicate reduced investor interest.
  • The month-to-month change in shares shorted has shown fluctuations, which could signal uncertainty in market sentiment.
  • While institutional ownership is high, it remains below 75%, which may suggest that there is still room for improvement in investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.11 billion
P/E Ratio
39.95
Consensus Rating
Moderate Buy
Consensus Price Target
$106.22 (+13.6% Upside)
Volume
1.69 million shares
Average Volume
1.06 million shares
Today's Range
$93.25
$95.07
50-Day Range
$82.86
$98.39
52-Week Range
$80.48
$101.10
Dividend Yield
0.28%
Takeda Pharmaceutical stock logo

34. Takeda Pharmaceutical NYSE:TAK

$13.73 -0.46 (-3.24%)
As of 05/13/2025 03:59 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.36, which is near its 1-year high of $15.43, indicating strong market performance.
  • Takeda Pharmaceutical Company Limited has a low P/E ratio of 35.90 compared to industry averages, suggesting potential undervaluation and room for growth.
  • The company has a solid market capitalization of $45.69 billion, reflecting its stability and presence in the pharmaceutical sector.

Cons of Takeda Pharmaceutical

  • The company reported earnings per share (EPS) of $0.16, missing analysts' expectations, which may raise concerns about its short-term profitability.
  • Takeda Pharmaceutical Company Limited's revenue for the last quarter was $7.34 billion, falling short of the $8.02 billion forecast, indicating potential challenges in meeting growth targets.
  • With a debt-to-equity ratio of 0.63, the company has a moderate level of debt, which could pose risks if market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.15 billion
P/E Ratio
34.33
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
2.90 million shares
Average Volume
1.90 million shares
Today's Range
$13.67
$13.97
50-Day Range
$13.73
$15.38
52-Week Range
$12.58
$15.43
Dividend Yield
3.72%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$75.48 +0.68 (+0.91%)
As of 05/13/2025 03:59 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $74.39, showing a recent increase, which may indicate positive market sentiment.
  • Edwards Lifesciences Co. reported a revenue increase of 6.2% year-over-year, reflecting strong business growth and demand for its medical research products.
  • The company has a solid return on equity of 19.40%, suggesting effective management and profitability, which can be attractive to investors.

Cons of Edwards Lifesciences

  • Insider selling has been notable, with the CEO recently selling shares, which may raise concerns about the company's future prospects.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 10.68, which could suggest that it is overvalued compared to its earnings.
  • Despite recent growth, the company faces competition in the medical research field, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.28 billion
P/E Ratio
10.83
Consensus Rating
Hold
Consensus Price Target
$79.60 (+5.5% Upside)
Volume
5.66 million shares
Average Volume
5.03 million shares
Today's Range
$74.08
$75.94
50-Day Range
$67.04
$76.28
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
IDEXX Laboratories stock logo

36. IDEXX Laboratories NASDAQ:IDXX

$509.13 -0.40 (-0.08%)
As of 05/13/2025 04:00 PM Eastern

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The company recently reported earnings per share of $2.96, exceeding analyst expectations, which indicates strong financial performance and effective management.
  • IDEXX Laboratories, Inc. has shown a year-over-year revenue growth of 3.6%, suggesting a positive trend in its business operations and market demand.
  • The current stock price is around $491.70, reflecting a robust market capitalization of approximately $39.85 billion, which can be attractive for investors looking for stability.

Cons of IDEXX Laboratories

  • Insider selling activity has been noted, with an executive recently selling nearly 10,000 shares, which may raise concerns about the company's future prospects from a management perspective.
  • Despite positive earnings, the stock has a high P/E ratio of 46.08, which could indicate that it is overvalued compared to its earnings, making it a riskier investment.
  • Recent downgrades from analysts, including a shift from "buy" to "hold" ratings, may signal a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.95 billion
P/E Ratio
47.72
Consensus Rating
Moderate Buy
Consensus Price Target
$524.75 (+3.1% Upside)
Volume
558,434 shares
Average Volume
648,081 shares
Today's Range
$504.20
$512.72
50-Day Range
$361.04
$509.53
52-Week Range
$356.14
$548.88
Dividend Yield
N/A
Veeva Systems stock logo

37. Veeva Systems NYSE:VEEV

$241.11 -0.33 (-0.14%)
As of 05/13/2025 03:59 PM Eastern

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $238, which reflects a strong market position and potential for growth.
  • Veeva Systems Inc. has received multiple "buy" ratings from analysts, indicating confidence in its future performance.
  • The company has a solid market capitalization of approximately $38.75 billion, suggesting stability and investor interest.

Cons of Veeva Systems

  • Insider sales have totaled 5,869 shares recently, which may raise concerns about the company's short-term outlook.
  • The stock has experienced fluctuations, with a twelve-month high of $258.93 and a low of $170.25, indicating volatility.
  • Some analysts have issued "hold" ratings, suggesting that the stock may not be a strong buy at current levels.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.23 billion
P/E Ratio
59.53
Consensus Rating
Moderate Buy
Consensus Price Target
$254.92 (+5.7% Upside)
Volume
1.40 million shares
Average Volume
1.09 million shares
Today's Range
$238.39
$243.13
50-Day Range
$209.34
$247.10
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
ResMed stock logo

38. ResMed NYSE:RMD

$248.03 +0.37 (+0.15%)
As of 05/13/2025 03:53 PM Eastern

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The company has demonstrated strong financial performance, reporting a net margin of over 25%, indicating effective cost management and profitability.
  • ResMed Inc. has a solid earnings forecast, with analysts projecting an EPS of approximately 9.47 for the current fiscal year, suggesting potential for growth in shareholder value.
  • The current stock price is around $290, reflecting positive market sentiment and investor confidence in the company's future prospects.

Cons of ResMed

  • Despite recent growth, the stock has faced price adjustments, with some analysts lowering their target prices, which may indicate potential volatility.
  • ResMed Inc. operates in a competitive market for medical devices, which could pressure margins and impact future profitability.
  • The company's dividend payout ratio is currently at 23.79%, which, while sustainable, may limit the potential for future dividend increases.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.37 billion
P/E Ratio
29.28
Consensus Rating
Moderate Buy
Consensus Price Target
$258.83 (+4.4% Upside)
Volume
2.15 million shares
Average Volume
1.01 million shares
Today's Range
$245.96
$248.85
50-Day Range
$204.54
$248.03
52-Week Range
$179.42
$263.05
Dividend Yield
0.87%
Cardinal Health stock logo

39. Cardinal Health NYSE:CAH

$148.28 -0.34 (-0.23%)
As of 05/13/2025 03:53 PM Eastern

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $148.36, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Cardinal Health, Inc. has received multiple upgrades from analysts, with price targets being raised, suggesting strong future performance expectations.
  • The company recently reported earnings that exceeded analysts' expectations, indicating robust financial health and operational efficiency.

Cons of Cardinal Health

  • The company has a negative return on equity, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Despite recent revenue growth, the company’s revenue fell short of analysts' expectations, which could indicate potential challenges in meeting future targets.
  • Cardinal Health, Inc. has a relatively high P/E ratio, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.39 billion
P/E Ratio
27.66
Consensus Rating
Moderate Buy
Consensus Price Target
$146.43 (-1.2% Downside)
Volume
2.29 million shares
Average Volume
2.21 million shares
Today's Range
$147.45
$149.21
50-Day Range
$124.07
$153.68
52-Week Range
$93.17
$154.07
Dividend Yield
1.37%
Alnylam Pharmaceuticals stock logo

40. Alnylam Pharmaceuticals NASDAQ:ALNY

$266.86 -3.33 (-1.23%)
As of 05/13/2025 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Recent analyst upgrades have significantly increased the price targets for Alnylam Pharmaceuticals, Inc., with some analysts setting targets as high as $353.00, indicating strong potential for price appreciation.
  • The current stock price is around $252.00, which is near its 50-day moving average, suggesting a potential for recovery and growth in the near term.
  • Alnylam Pharmaceuticals, Inc. reported a 20.2% year-over-year increase in quarterly revenue, showcasing strong business growth and demand for its products.

Cons of Alnylam Pharmaceuticals

  • The stock has experienced a recent decline of about 2.5%, which may indicate short-term volatility and uncertainty in the market.
  • Alnylam Pharmaceuticals, Inc. has a negative price-to-earnings ratio, which suggests that the company is not currently profitable, raising concerns about its financial health.
  • Insider selling has been notable, with executives selling shares recently, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.80 billion
P/E Ratio
-122.98
Consensus Rating
Moderate Buy
Consensus Price Target
$319.17 (+19.6% Upside)
Volume
723,502 shares
Average Volume
902,239 shares
Today's Range
$261.45
$268.07
50-Day Range
$224.32
$290.70
52-Week Range
$144.73
$304.39
Dividend Yield
N/A
GE HealthCare Technologies stock logo

41. GE HealthCare Technologies NASDAQ:GEHC

$73.83 -0.28 (-0.38%)
As of 05/13/2025 04:00 PM Eastern

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported earnings per share of $1.01, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • GE HealthCare Technologies Inc. has initiated a share repurchase program worth $1.00 billion, suggesting that the board believes the stock is undervalued, which can enhance shareholder value.
  • The current stock price is around $88, which is considered attractive given the company's solid revenue growth of 2.7% compared to the same quarter last year.

Cons of GE HealthCare Technologies

  • Recent price target reductions by several analysts, with some lowering their expectations significantly, may indicate concerns about future performance.
  • The stock has experienced volatility, with price targets ranging from $73 to $89, reflecting uncertainty in market sentiment.
  • Despite positive earnings, the company's net margin of 10.13% may be considered low compared to industry standards, which could limit profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.81 billion
P/E Ratio
17.05
Consensus Rating
Moderate Buy
Consensus Price Target
$88.27 (+19.6% Upside)
Volume
4.75 million shares
Average Volume
3.38 million shares
Today's Range
$73.67
$75.69
50-Day Range
$58.75
$86.58
52-Week Range
$57.65
$94.80
Dividend Yield
0.20%
argenx stock logo

42. argenx NASDAQ:ARGX

$542.47 -18.43 (-3.29%)
As of 05/13/2025 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • The current stock price is around $549, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • argenx SE recently reported earnings that significantly exceeded analysts' expectations, with an EPS of $2.58 compared to a consensus estimate of $0.98, indicating strong financial performance.
  • The company has a robust revenue stream, reporting $1.35 billion in revenue for the latest quarter, which is well above market expectations, showcasing its strong market position.

Cons of argenx

  • The company has a negative P/E ratio, indicating that it is currently not profitable, which can be a red flag for potential investors.
  • argenx SE has a negative net margin of 2.11%, suggesting that the company is not generating profit from its revenues, which could impact future growth.
  • Despite recent strong earnings, the company has a negative return on equity of 1.45%, indicating inefficiencies in generating profits from shareholders' equity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.12 billion
P/E Ratio
-616.44
Consensus Rating
Moderate Buy
Consensus Price Target
$697.94 (+28.7% Upside)
Volume
716,555 shares
Average Volume
320,161 shares
Today's Range
$538.09
$557.37
50-Day Range
$542.47
$656.65
52-Week Range
$352.77
$678.21
Dividend Yield
N/A
DexCom stock logo

43. DexCom NASDAQ:DXCM

$84.11 -0.94 (-1.11%)
As of 05/13/2025 04:00 PM Eastern

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $84.66, which reflects a potential for growth given recent analyst upgrades.
  • Investment analysts have recently raised the price target for DexCom, Inc. to $93.00, indicating a potential upside of nearly 10% from the current price.
  • DexCom, Inc. has received multiple buy ratings from analysts, suggesting strong confidence in the company's future performance.

Cons of DexCom

  • Insider sales have occurred recently, with executives selling shares, which could signal a lack of confidence in the stock's short-term performance.
  • The stock has experienced volatility, with a 1-year high of $132.26 and a low of $57.52, indicating potential risks for investors.
  • Analysts have varying opinions, with some lowering their price targets, which may create uncertainty about the stock's future direction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.98 billion
P/E Ratio
58.82
Consensus Rating
Moderate Buy
Consensus Price Target
$98.11 (+16.6% Upside)
Volume
5.51 million shares
Average Volume
4.32 million shares
Today's Range
$83.84
$85.54
50-Day Range
$59.83
$85.29
52-Week Range
$57.52
$132.26
Dividend Yield
N/A
Agilent Technologies stock logo

44. Agilent Technologies NYSE:A

$115.52 -0.03 (-0.03%)
As of 05/13/2025 03:59 PM Eastern

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $108, which reflects a recent increase, indicating positive market sentiment towards the company.
  • Agilent Technologies, Inc. has a strong market capitalization of approximately $30 billion, suggesting stability and growth potential in the medical research sector.
  • Recent analyst ratings show a consensus of "Moderate Buy," with several analysts issuing buy ratings, which can indicate confidence in the company's future performance.

Cons of Agilent Technologies

  • Recent analyst reports have shown a downward adjustment in target prices, with some analysts reducing their price objectives, which may indicate concerns about future growth.
  • The stock has experienced volatility, with a 52-week range showing a low of $96.43 and a high of $155.35, suggesting potential risks associated with price fluctuations.
  • Despite a strong market position, the company has a relatively high P/E ratio of 24.18, which may suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.94 billion
P/E Ratio
26.56
Consensus Rating
Hold
Consensus Price Target
$143.00 (+23.8% Upside)
Volume
2.75 million shares
Average Volume
1.89 million shares
Today's Range
$114.82
$116.88
50-Day Range
$98.97
$126.59
52-Week Range
$96.43
$155.35
Dividend Yield
0.86%
Centene stock logo

45. Centene NYSE:CNC

$59.02 -3.85 (-6.12%)
As of 05/13/2025 03:59 PM Eastern

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is around $62.82, which is relatively stable compared to its 12-month high of $80.59, indicating potential for recovery and growth.
  • Centene Co. reported a significant increase in quarterly revenue, reaching $46.62 billion, which surpassed analysts' expectations and reflects strong operational performance.
  • The company has a low price-to-earnings (P/E) ratio of 10.07, suggesting that the stock may be undervalued compared to its earnings, making it an attractive investment opportunity.

Cons of Centene

  • Recent downgrades from analysts, including a reduction from "buy" to "hold" by Argus, may signal concerns about the company's future performance.
  • The stock has a relatively low beta of 0.48, indicating lower volatility, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Centene Co. has a debt-to-equity ratio of 0.70, which, while manageable, suggests that the company is somewhat reliant on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.37 billion
P/E Ratio
9.46
Consensus Rating
Moderate Buy
Consensus Price Target
$79.77 (+35.2% Upside)
Volume
8.66 million shares
Average Volume
4.81 million shares
Today's Range
$58.95
$61.14
50-Day Range
$57.74
$64.37
52-Week Range
$55.03
$80.59
Dividend Yield
N/A
Humana stock logo

46. Humana NYSE:HUM

$229.13 -23.73 (-9.38%)
As of 05/13/2025 03:59 PM Eastern

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. has shown strong earnings growth potential, with recent estimates indicating earnings per share of $5.71 for Q2 2025, reflecting an increase from previous forecasts.
  • The current stock price is around $249.67, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Analysts have a generally positive outlook, with several firms upgrading their ratings and price targets, suggesting confidence in the company's future performance.

Cons of Humana

  • Despite positive growth forecasts, the stock has experienced volatility, with a 52-week high of $406.46 and a low of $213.31, indicating potential risks associated with price fluctuations.
  • Recent trading activity shows a decline, with shares down about 1.5% recently, which may raise concerns about short-term performance.
  • Some analysts have issued neutral ratings, suggesting that while there is potential, there may also be caution regarding the stock's immediate prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.65 billion
P/E Ratio
23.03
Consensus Rating
Hold
Consensus Price Target
$286.81 (+25.2% Upside)
Volume
3.84 million shares
Average Volume
1.75 million shares
Today's Range
$228.57
$244.43
50-Day Range
$229.13
$294.97
52-Week Range
$213.31
$406.46
Dividend Yield
1.40%
IQVIA stock logo

47. IQVIA NYSE:IQV

$150.74 -5.39 (-3.45%)
As of 05/13/2025 03:59 PM Eastern

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $150, which may present a buying opportunity for investors looking for value in the medical research sector.
  • IQVIA Holdings Inc. reported a quarterly revenue increase of 2.5% compared to the same quarter last year, indicating growth potential in its business operations.
  • The company has a strong return on equity of 28.81%, suggesting effective management and profitability, which can be attractive to investors seeking solid financial performance.

Cons of IQVIA

  • The stock has experienced volatility, with a 12-month high of $252.88 and a low of $135.97, indicating potential risks associated with price fluctuations.
  • Recent price target reductions by analysts suggest that some experts may have concerns about the company's near-term performance.
  • The company has a relatively high debt-to-equity ratio of 2.12, which may raise concerns about financial leverage and risk in a downturn.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.08 billion
P/E Ratio
20.10
Consensus Rating
Moderate Buy
Consensus Price Target
$231.71 (+53.7% Upside)
Volume
2.50 million shares
Average Volume
1.49 million shares
Today's Range
$150.61
$155.95
50-Day Range
$141.38
$191.69
52-Week Range
$135.97
$252.88
Dividend Yield
N/A
Mettler-Toledo International stock logo

48. Mettler-Toledo International NYSE:MTD

$1,182.90 +8.31 (+0.71%)
As of 05/13/2025 03:53 PM Eastern

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,079.96, which may present a buying opportunity for investors looking for growth in the medical instruments sector.
  • Mettler-Toledo International Inc. reported earnings per share (EPS) of $8.19, exceeding analysts' expectations, indicating strong financial performance.
  • The company has a market capitalization of approximately $22.44 billion, reflecting its significant presence and stability in the market.

Cons of Mettler-Toledo International

  • The stock has experienced a decline of about 2% recently, which may indicate short-term volatility and risk for investors.
  • Analysts have mixed ratings, with some maintaining a "hold" rating, suggesting uncertainty about future performance.
  • The company reported a revenue decrease of 4.6% compared to the same quarter last year, which could signal challenges in maintaining growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.58 billion
P/E Ratio
29.19
Consensus Rating
Hold
Consensus Price Target
$1,296.13 (+9.6% Upside)
Volume
244,505 shares
Average Volume
145,146 shares
Today's Range
$1,169.81
$1,189.90
50-Day Range
$969.01
$1,296.16
52-Week Range
$946.69
$1,546.93
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$24.22 -0.82 (-3.27%)
As of 05/13/2025 03:59 PM Eastern

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $25, showing a recent increase, which may indicate positive market sentiment.
  • Koninklijke Philips reported a revenue of $5.38 billion in its latest quarter, exceeding analysts' expectations, suggesting strong operational performance.
  • The company has a positive return on equity of 10.85%, indicating effective management in generating profits from shareholders' equity.

Cons of Koninklijke Philips

  • The company has a negative net margin of 3.88%, indicating that it is currently spending more than it earns, which could be a concern for profitability.
  • Recent dividend cuts may signal financial strain, as the payout ratio is currently negative, suggesting that the company is not generating enough profit to support its dividend payments.
  • With a price-to-earnings ratio of around -29.82, the stock may be considered overvalued, as it indicates that the company is not currently profitable.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$22.77 billion
P/E Ratio
-28.83
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.21 million shares
Average Volume
811,377 shares
Today's Range
$24.03
$24.33
50-Day Range
$21.68
$27.58
52-Week Range
$21.48
$32.91
Dividend Yield
3.80%
STERIS stock logo

50. STERIS NYSE:STE

$231.15 -1.95 (-0.84%)
As of 05/13/2025 03:59 PM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. More about STERIS

Pros of STERIS

  • The current stock price is around $223, which is relatively stable compared to its 12-month high of $248.24, indicating potential for growth.
  • STERIS plc has a strong market capitalization of approximately $22.26 billion, suggesting a solid position in the medical equipment industry.
  • The company reported a return on equity of 13.91%, reflecting effective management and profitability, which can be attractive to investors looking for reliable returns.

Cons of STERIS

  • The price-to-earnings ratio of 48.10 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • STERIS plc recently missed earnings expectations by $0.01, which may raise concerns about its ability to meet future financial targets.
  • The company's beta of 0.96 indicates that it is slightly less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$22.71 billion
P/E Ratio
49.08
Consensus Rating
Buy
Consensus Price Target
$258.75 (+11.9% Upside)
Volume
570,579 shares
Average Volume
533,819 shares
Today's Range
$230.70
$233.11
50-Day Range
$208.26
$233.02
52-Week Range
$200.98
$248.24
Dividend Yield
1.01%